TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.


NEWS
 Á¦¸ñ : [°øÁö] LV & AAV Transfection Platforms for Gene Therapy – µ¿¿µ»ó¾÷·Îµå
ÀÛ¼ºÀÏ : 2020.09.15
 ÀÛ¼ºÀÚ : ´ÙÄ«¶óÄÚ¸®¾Æ

[µ¿¿µ»ó¾÷·Îµå] Lentivi & AAV Transfection Platforms for Gene Therapy

 

 

Transfection Àü¹®±â¾÷ Mirus¿¡¼­ ÁøÇàÇÑ

¡®How LV and AAV Transfection Platforms will Shape the Future of Gene Therapy Manufacturing¡¯ webinar µ¿¿µ»óÀ»

Áö±Ý, ´ÙÄ«¶óÄÚ¸®¾Æ ȨÆäÀÌÁö¿¡¼­ È®ÀÎÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.

 

[Mirus] Transfection for Virus production webinar µ¿¿µ»ó º¸·¯°¡±â (¸µÅ©)

 

Learning Objectives:

  • Introduce TransIT-VirusGEN¢ç LV and AAV Kits for development and manufacture of Cell and Gene Therapies
  • Understand the need for increasing manufacturing efficiency to generate sufficient doses for large patient populations
  • Highlight the TransIT-VirusGEN¢ç SELECT and upcoming GMP Products and quality control documentation
  • Demonstrate critical parameters for optimized virus production using TransIT-VirusGEN¢ç Reagent and Kits

 

±× ¿Ü ¹®ÀÇ»çÇ×Àº °í°´Áö¿ø¼¾ÅÍ (02-2081-2510, support@takara.co.kr) ·Î ¿¬¶ô¹Ù¶ø´Ï´Ù.

°¨»çÇÕ´Ï´Ù.

 ¸ñ·ÏÀ¸·Î